Cogent Biosciences Inc Stock Price, News & Analysis

Cogent Biosciences has announced initial data from its APEX trial of bezuclastinib, targeting advanced systemic mastocytosis, to be presented at the European Hematology Association 2022 meeting. The company reported a cash balance of $191 million at the end of Q1 2022, sufficient to fund operations into 2024. R&D expenses surged to $25.5 million from $8.2 million year-over-year, while the net loss widened to $30.6 million from $11.7 million. Cogent is progressing multiple clinical trials and research programs, enhancing its oncology pipeline.

Cogent Biosciences, a biotechnology company focused on precision therapies for genetically defined diseases, announced management's participation in a fireside chat at the LifeSci Partners Immunology and Inflammation Symposium on May 10, 2022, at 3:30 p.m. ET. The event will be accessible via a live audio webcast on the company's website, with an archived replay available for 30 days. Cogent's lead program, bezuclastinib, targets the KIT D816V mutation and other KIT exon 17 mutations, which are linked to systemic mastocytosis and gastrointestinal stromal tumors (GIST).

Cogent Biosciences (COGT) presented new nonclinical data for bezuclastinib at the AACR annual meeting, indicating its potential as a best-in-class KIT mutant inhibitor, particularly for systemic mastocytosis and gastrointestinal stromal tumors (GIST). The data highlight its selectivity against related kinases and minimal brain penetration. The company also continues to advance its FGFR2 and ErbB2 inhibitor programs, with plans to file an IND for FGFR2 in the latter half of 2023. Initial APEX trial results are expected later this quarter.

On March 29, 2022, Cogent Biosciences (Nasdaq: COGT) announced a Virtual R&D Investor Event scheduled for April 8, 2022, at 4:05 PM EDT. The event will include updates on nonclinical data for bezuclastinib, a KIT mutant inhibitor, and insights into their strategy for developing small molecules for genetically defined diseases. Featured speakers include Andrew Robbins, John Robinson, and Jessica Sachs. Additionally, Cogent will present two posters at the AACR Annual Meeting 2022, showcasing new data on bezuclastinib and FGFR inhibitors. Registration for the event is available online.

Cogent Biosciences, Inc. (Nasdaq: COGT) announced its financial results for 2021, reporting a net loss of $72.3 million, with R&D expenses rising to $55.9 million due to ongoing clinical trials for its drug bezuclastinib. The company ended the year with $219.7 million in cash, projected to sustain operations through 2024. Currently, Cogent is actively enrolling patients in three late-stage bezuclastinib trials: APEX, SUMMIT, and PEAK. Initial data from the APEX trial is expected in the first half of 2022, alongside an R&D Investor Event scheduled for April 8, 2022.

Cogent Biosciences (Nasdaq: COGT) announced the upcoming presentation of two abstracts at the AACR Annual Meeting, taking place from April 8-13, 2022, in New Orleans, Louisiana. The presentations will focus on the unique properties of bezuclastinib, a selective KIT inhibitor, and a novel series of FGFR2 inhibitors. The first poster highlights nonclinical data showcasing bezuclastinib's differentiation from other KIT inhibitors, while the second explores the potency of FGFR inhibitors against mutations. Both presentations are scheduled for April 10, 2022.

Cogent Biosciences (Nasdaq: COGT) released updates for 2021 and guidance for 2022, highlighting progress in developing therapies for genetically defined diseases. In 2021, they initiated three late-stage clinical trials for bezuclastinib, targeting systemic mastocytosis and gastrointestinal stromal tumors. Preliminary data from the APEX trial is anticipated in early 2022. The formation of the Cogent Research Team aims to expand their pipeline of novel compounds. The company is set to host an R&D investor event in April 2022 to further discuss their research advancements.

Cogent Biosciences (Nasdaq: COGT) announced that CEO Andrew Robbins will participate in a fireside chat and one-on-one investor meetings at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. The pre-recorded chat will be available starting at 10:00 a.m. ET and accessible until the conference concludes. Cogent focuses on precision therapies for genetically defined diseases, with its lead program, bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and advanced gastrointestinal stromal tumors.

Cogent Biosciences, a biotechnology firm, announced its Q3 2021 financial results on November 10, 2021. The company reported R&D expenses of $14.8 million, significantly up from $5.0 million in Q3 2020. Net loss for the quarter was $19.1 million, an improvement compared to $50.0 million a year prior. Cash and cash equivalents as of September 30, 2021, stood at $202.9 million, sufficient to fund operations into 2024. The SUMMIT trial for bezuclastinib in systemic mastocytosis has begun, with other trials anticipated in 2022.